市場調査レポート

商品コード

1609454

慢性閉塞性肺疾患 (COPD) 治療薬市場の評価：タイプ・薬剤クラス・流通チャネル・地域別の機会および予測 (2018-2032年)

Chronic Obstructive Pulmonary Disease Treatment Market Assessment, By Type, By Drug Class, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F

出版日: 2024年12月11日
発行: Market Xcel - Markets and Data
ページ情報: 英文 248 Pages
納期: 3～5営業日

カスタマイズ可能

価格

PDF & Excel Printable (Single User License)

USD 4,500 661,455円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 837,843円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,205,318円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.99円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の慢性閉塞性肺疾患 (COPD) 治療薬の市場規模は、2024年の223億1,000万米ドルから、予測期間中はCAGR 4.55%で推移し、2032年には318億4,000万米ドルの規模に成長すると予測されています。

高齢化社会の急速な拡大、大気汚染の深刻化、喫煙者の増加などが、世界の慢性閉塞性肺疾患 (COPD) 治療薬市場の需要を押し上げる主な要因となっています。COPDは通常、肺気腫と気管支炎の両方を伴う疾患で、世界中で数百万人が罹患していることで知られています。COPDの治療には通常、副腎皮質ステロイドや吸入気管支拡張薬などが用いられ、患者のQOL (生活の質) や呼吸機能を改善します。治療計画には様々な薬理学的、非薬理学的介入が統合されることが多いです。

高齢化人口の急速な拡大も市場の成長を支えています。世界保健機関 (WHO) の推計では、2030年までに全世界の6人に1人が60歳以上になるとされています。COPDの有病率は、若年層よりも60歳以上の方が2～3倍高いため、この成長が同市場の需要を高めています。さらに、患者アドヒアランス技術、デジタル治療、先進的な治療アプローチに焦点を当てた投資の増加、個別化COPD治療薬に取り組むバイオ製薬企業の増加も、市場に有利な成長機会をもたらしています。

さらに、COPDの治療と管理のための革新的なソリューションのアベイラビリティを確保するための市場の主要企業による献身的な努力も、COPD治療薬市場に有利な成長機会を提供しています。また、世界の医療組織や政府機関も、COPDの脅威の増大に対処し、革新的な治療法への患者のアクセスを改善するために、COPDに関する認知度を高め、さまざまな治療ソリューションを利用できるように取り組んでいます。

当レポートでは、世界の慢性閉塞性肺疾患 (COPD) 治療薬の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

上位5社の競合マトリックス
上位5社のSWOT分析
上位10社の情勢
- AstraZeneca PLC
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Boehringer Ingelheim International GmbH
- Sanofi S.A.
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Almirall, S.A.

第21章戦略的提言

第22章当社について・免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Region, 2018-2032F
Figure 6. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 7. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 8. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 9. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 10. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Country, 2018-2032F
Figure 11. United States Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 12. United States Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 13. United States Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 14. United States Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 15. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 16. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 17. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 18. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 19. Mexico Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 20. Mexico Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 21. Mexico Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 22. Mexico Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 23. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 24. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 25. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 26. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 27. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Country, 2018-2032F
Figure 28. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 29. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 30. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 31. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 32. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 33. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 34. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 35. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 36. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 37. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 38. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 39. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 40. United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 41. United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 42. United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 43. United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 44. Russia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 45. Russia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 46. Russia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 47. Russia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 48. Netherlands Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 49. Netherlands Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 50. Netherlands Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 51. Netherlands Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 52. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 53. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 54. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 55. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 56. Turkey Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 57. Turkey Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 58. Turkey Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 59. Turkey Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 60. Poland Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 61. Poland Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 62. Poland Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 63. Poland Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 64. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 65. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 66. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 67. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 68. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Country, 2018-2032F
Figure 69. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 70. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 71. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 72. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 73. Argentina Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 74. Argentina Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 75. Argentina Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 76. Argentina Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 77. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 78. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 79. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 80. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 81. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Country, 2018-2032F
Figure 82. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 83. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 84. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 85. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 86. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 87. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 88. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 89. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 90. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 91. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 92. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 93. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 94. Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 95. Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 96. Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 97. Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 98. Vietnam Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 99. Vietnam Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 100. Vietnam Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 101. Vietnam Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 102. South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 103. South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 104. South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 105. South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 106. Indonesia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 107. Indonesia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 108. Indonesia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 109. Indonesia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 110. Philippines Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 111. Philippines Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 112. Philippines Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 113. Philippines Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 114. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 115. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 116. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 117. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 118. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Country, 2018-2032F
Figure 119. Saudi Arabia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 120. Saudi Arabia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 121. Saudi Arabia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 122. Saudi Arabia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 123. UAE Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 124. UAE Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 125. UAE Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 126. UAE Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 127. South Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 128. South Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
Figure 129. South Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
Figure 130. South Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 131. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 132. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 133. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024

Product Code: MX12381

Global chronic obstructive pulmonary disease (COPD) treatment market is projected to witness a CAGR of 4.55% during the forecast period 2025-2032, growing from USD 22.31 billion in 2024 to USD 31.84 billion in 2032. The rapid expansion of the aging population, growing air pollution, and increasing popularity of smoking are some of the major factors bolstering the global chronic obstructive pulmonary disease (COPD) treatment market demand. The condition usually involves both emphysema and bronchitis and is known for affecting millions of individuals across the globe. The treatment for COPD usually involves corticosteroids and inhaled bronchodilators, among other therapies that improve the patients' quality of life and respiratory functioning. The treatment plans often integrate various pharmacologic and non-pharmacologic interventions.

The rapid expansion of the aging population also supports the market's growth. As per the estimates of the World Health Organization (WHO), one in six people across the globe will be sixty or older by 2030. This growth is bolstering the demand for the global chronic obstructive pulmonary disease (COPD) treatment market as the prevalence of the condition is two to three times higher in individuals over the age of sixty than in individuals from younger age groups. Furthermore, rising investments focused on patient adherence technologies, digital therapeutics, and advanced therapeutic approaches, coupled with an increasing number of biopharmaceutical companies working on personalized COPD treatment, also provide lucrative growth opportunities to the market.

Additionally, the dedicated efforts by the market's key players to ensure the availability of innovative solutions for treating and managing COPD also provide lucrative growth opportunities to the COPD treatment market. In May 2024, AstraZeneca PLC unveiled its latest research on immune-mediated and respiratory diseases at the American Thoracic Society (ATS) International Conference 2024. Meanwhile, healthcare organizations and government institutions across the globe are working on increasing awareness about COPD and the availability of different treatment solutions to address the growing threat of the disease and improve patient access to innovative therapies.

Increasing Approvals from Regulatory Bodies to Provide New Growth Opportunities

The different regulatory bodies across the globe are providing approval for various treatment solutions for COPD to aid patients suffering from uncontrolled COPD. In September 2024, the Medicines and Healthcare Products Agency (MHRA) authorized the usage of Dupilumab for treating uncontrolled COPD in the U.K. Dupilumab, a monoclonal antibody that inhibits the signaling of the interleukin-13 (IL13) and interleukin-4 (IL4) pathway, reduces type 2 inflammation observed in approximately 30-40% of patients with COPD. After receiving positive results from phase III clinical trials, the regulatory body has granted marketing authorization for subcutaneous injections as an add-on for maintenance treatment in adults with uncontrolled COPD.

Additionally, regulatory bodies increasingly provide accelerated approvals for novel treatment devices, drugs, and combination therapies to ensure patient access to advanced treatment solutions, driving innovation and positively influencing the market's expansion. Such approvals are essential as they aid in validating the efficacy and safety of the treatment solutions while fostering competition and allowing companies to introduce novel products.

Rising Research and Development Activities Support Market Expansion

The growing emphasis on research activities to bolster the availability of treatment solutions essential for treating COPD is a major global chronic obstructive pulmonary disease (COPD) treatment market driver. As the disease continues to impact millions across the globe, investments in research and development activities are rising to ensure the availability of effective treatment options. The multifaced research and development initiatives are targeting the development of innovative drugs, personalized medicines, and advanced inhalation devices to play a transformative role in managing COPD. For instance, in February 2024, ReAlta Life Sciences, Inc. initiated enrollment for the Phase II clinical trial of the RLS-0071 drug targeting acute exacerbations of COPD. The placebo-controlled, randomized, and double-blind trial assessed the pharmacokinetics, safety, efficacy, and pharmacokinetic-pharmacodynamic links of RLS-0071.

Additionally, the increasing collaborations between research institutions, healthcare providers, and pharmaceutical companies to address the complexities of COPD also provide lucrative growth opportunities to the market. Such partnerships and collaborations ensure cross-sector expertise sharing and support the development of advanced treatment solutions.

Hospital Pharmacies Account for Significant Market Share

Hospital pharmacies account for a significant share of the market owing to a wide range of factors, such as the unique dynamics of hospital settings and complex requirements for effective management of the condition. These pharmacies are essential for providing direct patient care to manage chronic health conditions such as COPD effectively. Pharmacists in these settings possess specialized knowledge and training in various respiratory medications, including combination therapies, corticosteroids, and bronchodilators. Furthermore, hospital pharmacies are equipped with a wide range of specialized formulations and advanced therapeutics which are often unavailable in retail pharmacies.

Additionally, hospital pharmacies across the globe are deploying technologically advanced solutions to facilitate efficient, safe, and accurate dispensing and management of drugs. As per the 2023 American Society of Health-System Pharmacists (ASHP) National Survey of Pharmacy Practice in Hospital Settings: Operations and Technology, approximately 73.6% of the hospitals surveyed utilize machine-readable coding for verifying doses during dispensing. Such efforts are also bolstering the segment's expansion.

North America is Anticipated to Hold a Major Market Share Over the Forecast Period

The expansion of the North America chronic obstructive pulmonary disease (COPD) treatment market can be attributed to the high acceptance and accessibility of novel diagnostic and treatment options and the strong presence of leading pharmaceutical companies in the region. Due to the rising prevalence of the condition in the region, the demand for effective treatment and management solutions is rising. According to the estimates of the Canadian Lung Association, over 2 million Canadians are affected by COPD, and it is one of the leading causes of hospitalization in Canada. The institute also estimates that there are approximately 1 million undiagnosed COPD population in the country.

The presence of different organizations, such as the American Association for Respiratory Care (AARC), that are dedicated to increasing awareness about lung health and treatment options available for various respiratory diseases, is also supporting the market's expansion. Furthermore, the strong presence of public and private healthcare systems in countries such as Canada and the United States is ensuring the affordability of COPD medication due to the widespread insurance coverage, bolstering the market's growth in North America.

Future Market Scenario (2024-2031F)

As per the global chronic obstructive pulmonary disease (COPD) treatment market analysis, the market is expected to witness significant growth in the coming years owing to the increasing efforts of the leading pharmaceutical companies to bolster the availability of novel therapies and the increasing prevalence of COPD. According to estimates from a modeling study published in the JAMA Network of the American Medical Association, by 2050, a relative growth of 23% in the number of patients with COPD will be witnessed compared to 2020.

Additionally, increasing government support and healthcare policy reforms across different regions are also expected to aid in addressing the cost-related challenges associated with COPD treatment, boosting patient access to the different treatment solutions. Innovative healthcare approaches, including precision medicine and digital healthcare solutions, are also anticipated to play a crucial role in COPD management and aid healthcare professionals in providing more effective and personalized treatment options. With the rise in investments in healthcare research and growing emphasis on developing innovative therapeutic solutions, the global chronic obstructive pulmonary disease (COPD) treatment market is expected to rapidly expand and aid patients in effectively managing the condition and improving their quality of life.

Key Players Landscape and Outlook

Key market players are actively investing in developing and introducing novel products in the market to aid patients suffering from COPD to manage the condition effectively. With the help of fast-track and breakthrough therapy designations for novel maintenance treatments for COPD, various regulatory bodies support such efforts. For instance, in August 2024, the Food and Drug Administration (FDA) granted breakthrough therapy designation as an add-on treatment for patients suffering from very severe to moderate COPD with a high blood count of eosinophils to AstraZeneca PLC and Amgen Inc.'s Tezspire. The primary intent of the breakthrough therapy designation is to provide interactive communications and timely advice to aid sponsors in conducting and designing drug development programs efficiently.

Similarly, in September 2024, Regeneron Pharmaceuticals, Inc. and Sanofi S.A.'s drug for treating COPD received approval from the FDA. Dupixent, the first biologic medicine approved in the United States for treating COPD, showed a 30% reduction in the annualized rate of COPD in a pair of Phase 3 studies. The drug had previously been approved for treating other conditions, such as asthma and atopic dermatitis. After receiving approval from the regulatory body, both companies witnessed a spike in their shares.

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F

4.1. Market Size Analysis & Forecast
- 4.1.1. By Value
4.2. Market Share Analysis & Forecast
- 4.2.1. By Type
  - 4.2.1.1. Emphysema
  - 4.2.1.2. Chronic Bronchitis
- 4.2.2. By Drug Class
  - 4.2.2.1. Combination Therapy
  - 4.2.2.2. Bronchodilators
  - 4.2.2.3. Corticosteroids
  - 4.2.2.4. Phosphodiesterase Type 4 Inhibitor
  - 4.2.2.5. Mucokinetics
  - 4.2.2.6. Others
- 4.2.3. By Distribution Channel
  - 4.2.3.1. Hospital Pharmacies
  - 4.2.3.2. Retail Pharmacies
  - 4.2.3.3. Online Pharmacies
- 4.2.4. By Region
  - 4.2.4.1. North America
  - 4.2.4.2. Europe
  - 4.2.4.3. Asia-Pacific
  - 4.2.4.4. South America
  - 4.2.4.5. Middle East and Africa
- 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
4.3. Market Map Analysis, 2024
- 4.3.1. By Type
- 4.3.2. By Drug Class
- 4.3.3. By Distribution Channel
- 4.3.4. By Region

5. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F*

5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
5.2. Market Share Analysis & Forecast
- 5.2.1. By Type
  - 5.2.1.1. Emphysema
  - 5.2.1.2. Chronic Bronchitis
- 5.2.2. By Drug Class
  - 5.2.2.1. Combination Therapy
  - 5.2.2.2. Bronchodilators
  - 5.2.2.3. Corticosteroids
  - 5.2.2.4. Phosphodiesterase Type 4 Inhibitor
  - 5.2.2.5. Mucokinetics
  - 5.2.2.6. Others
- 5.2.3. By Distribution Channel
  - 5.2.3.1. Hospital Pharmacies
  - 5.2.3.2. Retail Pharmacies
  - 5.2.3.3. Online Pharmacies
- 5.2.4. By Country Share
  - 5.2.4.1. United States
  - 5.2.4.2. Canada
  - 5.2.4.3. Mexico
5.3. Country Market Assessment
- 5.3.1. United States Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F*
  - 5.3.1.1. Market Size Analysis & Forecast
    - 5.3.1.1.1. By Value
  - 5.3.1.2. Market Share Analysis & Forecast
    - 5.3.1.2.1. By Type
      - 5.3.1.2.1.1. Emphysema
      - 5.3.1.2.1.2. Chronic Bronchitis
    - 5.3.1.2.2. By Drug Class
      - 5.3.1.2.2.1. Combination Therapy
      - 5.3.1.2.2.2. Bronchodilators
      - 5.3.1.2.2.3. Corticosteroids
      - 5.3.1.2.2.4. Phosphodiesterase Type 4 Inhibitor
      - 5.3.1.2.2.5. Mucokinetics
      - 5.3.1.2.2.6. Others
    - 5.3.1.2.3. By Distribution Channel
      - 5.3.1.2.3.1. Hospital Pharmacies
      - 5.3.1.2.3.2. Retail Pharmacies
      - 5.3.1.2.3.3. Online Pharmacies
- 5.3.2. Canada
- 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F

6.1. Germany
6.2. France
6.3. Italy
6.4. United Kingdom
6.5. Russia
6.6. Netherlands
6.7. Spain
6.8. Poland

7. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F

7.1. India
7.2. China
7.3. Japan
7.4. Australia
7.5. Vietnam
7.6. South Korea
7.7. Indonesia
7.8. Philippines

8. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F

8.1. Brazil
8.2. Argentina

9. Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F

9.1. Saudi Arabia
9.2. UAE
9.3. South Africa
9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

15.1. Market Drivers
15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

17.1. Clinical Trials
17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

20.1. Competition Matrix of Top 5 Market Leaders
20.2. SWOT Analysis for Top 5 Players
20.3. Key Players Landscape for Top 10 Market Players
- 20.3.1. AstraZeneca PLC
  - 20.3.1.1. Company Details
  - 20.3.1.2. Key Management Personnel
  - 20.3.1.3. Products and Services
  - 20.3.1.4. Financials (As Reported)
  - 20.3.1.5. Key Market Focus and Geographical Presence
  - 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
- 20.3.2. Pfizer Inc.
- 20.3.3. Teva Pharmaceutical Industries Ltd.
- 20.3.4. Novartis AG
- 20.3.5. F. Hoffmann-La Roche Ltd
- 20.3.6. Boehringer Ingelheim International GmbH
- 20.3.7. Sanofi S.A.
- 20.3.8. GlaxoSmithKline plc
- 20.3.9. Merck & Co., Inc.
- 20.3.10. Almirall, S.A.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

慢性閉塞性肺疾患 (COPD) 治療薬市場の評価：タイプ・薬剤クラス・流通チャネル・地域別の機会および予測 (2018-2032年)

Chronic Obstructive Pulmonary Disease Treatment Market Assessment, By Type, By Drug Class, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の慢性閉塞性肺疾患 (COPD) 治療薬市場の展望

第5章 北米慢性閉塞性肺疾患 (COPD) 治療薬市場の展望

第6章 欧州の慢性閉塞性肺疾患 (COPD) 治療薬市場の展望

第7章 アジア太平洋の慢性閉塞性肺疾患 (COPD) 治療薬市場の展望

第8章 南米の慢性閉塞性肺疾患 (COPD) 治療薬市場の展望

第9章 中東・アフリカの慢性閉塞性肺疾患 (COPD) 治療薬市場の展望

第10章 需給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

第16章 市場動向・展開

第17章 法規制の枠組み・イノベーション

第18章 特許情勢

第19章 ケーススタディ

第20章 競合情勢

第21章 戦略的提言

第22章 当社について・免責事項

List of Tables

List of Figures

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F

5. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F*

6. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F

7. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F

8. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F

9. Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

16. Market Trends and Developments

17. Regulatory Framework and Innovation

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

21. Strategic Recommendations

22. About Us and Disclaimer

第1章プロジェクトの範囲と定義

第2章調査手法

第3章エグゼクティブサマリー

第4章世界の慢性閉塞性肺疾患 (COPD) 治療薬市場の展望

第5章北米慢性閉塞性肺疾患 (COPD) 治療薬市場の展望

第6章欧州の慢性閉塞性肺疾患 (COPD) 治療薬市場の展望

第7章アジア太平洋の慢性閉塞性肺疾患 (COPD) 治療薬市場の展望

第8章南米の慢性閉塞性肺疾患 (COPD) 治療薬市場の展望

第9章中東・アフリカの慢性閉塞性肺疾患 (COPD) 治療薬市場の展望

第10章需給分析

第11章バリューチェーン分析

第12章ポーターのファイブフォース分析

第14章価格分析

第15章市場力学

第16章市場動向・展開

第17章法規制の枠組み・イノベーション

第18章特許情勢

第19章ケーススタディ

第20章競合情勢

第21章戦略的提言

第22章当社について・免責事項